Motor speech disorders in the nonfluent, semantic and logopenic variants of primary progressive aphasia.


Journal

Cortex; a journal devoted to the study of the nervous system and behavior
ISSN: 1973-8102
Titre abrégé: Cortex
Pays: Italy
ID NLM: 0100725

Informations de publication

Date de publication:
07 2021
Historique:
received: 29 10 2020
revised: 12 02 2021
accepted: 22 03 2021
pubmed: 3 5 2021
medline: 25 6 2021
entrez: 2 5 2021
Statut: ppublish

Résumé

Motor speech disorders (MSDs) are characteristic for nonfluent primary progressive aphasia (nfvPPA). In primary progressive aphasia (PPA) of the semantic (svPPA) and of the logopenic type (lvPPA), speech motor function is considered typically intact. However, knowledge on the prevalence of MSDs in svPPA and lvPPA is mainly based on studies with a priori knowledge of PPA syndrome diagnosis. This fully blinded retrospective study aims to provide data on the prevalence of all types of MSDs in a large sample of German-speaking patients with different subtypes of PPA. Two raters, blinded for PPA subtype, independently evaluated connected speech samples for MSD syndrome and severity from 161 patients diagnosed with nfvPPA, svPPA or lvPPA in the database of the German Consortium of Frontotemporal Lobar Degeneration (FTLDc). In case of disagreement, a third experienced rater re-evaluated the speech samples, followed by a consensus procedure. Consensus was reached for 160 patients (74 nfvPPA, 49 svPPA, 37 lvPPA). Across all PPA syndromes, 43.8% of the patients showed MSDs. Patients with nfvPPA demonstrated the highest proportion of MSDs (62.2%), but MSDs were also identified in svPPA (26.5%) and lvPPA (29.7%), respectively. Overall, dysarthria was the most common class of MSDs, followed by apraxia of speech. In addition, we identified speech abnormalities presenting as "syllabic speech", "dysfluent speech", and "adynamic speech". Our study confirmed MSDs as frequently occurring in PPA. The study also confirmed MSDs to be most common in patients with nfvPPA. However, MSDs were also found in substantial proportions of patients with svPPA and lvPPA. Furthermore, our study identified speech motor deficits that have not received attention in previous studies on PPA. The results are discussed against the background of the existing literature on MSDs in PPA, including theoretical considerations of the neuroanatomical conditions described for each of the different subtypes of PPA.

Identifiants

pubmed: 33933931
pii: S0010-9452(21)00118-0
doi: 10.1016/j.cortex.2021.03.017
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

66-79

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Anja Staiger (A)

Clinical Neuropsychology Research Group (EKN), Institute of Phonetics and Speech Processing, Ludwig-Maximilians-Universität (LMU) München, München, Germany. Electronic address: anja.staiger@ekn-muenchen.de.

Matthias L Schroeter (ML)

Max Planck Institute for Human Cognitive and Brain Sciences Leipzig & Clinic for Cognitive Neurology, University Hospital Leipzig, Germany.

Wolfram Ziegler (W)

Clinical Neuropsychology Research Group (EKN), Institute of Phonetics and Speech Processing, Ludwig-Maximilians-Universität (LMU) München, München, Germany.

Theresa Schölderle (T)

Clinical Neuropsychology Research Group (EKN), Institute of Phonetics and Speech Processing, Ludwig-Maximilians-Universität (LMU) München, München, Germany.

Sarah Anderl-Straub (S)

Department of Neurology, University of Ulm, Ulm, Germany.

Adrian Danek (A)

Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität (LMU) München, München, Germany.

Thomas Duning (T)

Department of Neurology, University of Münster, Münster, Germany.

Klaus Fassbender (K)

Department of Neurology, Saarland University, Homburg, Germany.

Klaus Fliessbach (K)

Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Medicine Bonn & DZNE Bonn, Bonn, Germany.

Holger Jahn (H)

Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Elisabeth Kasper (E)

Department of Neurology, Rostock University Medical Center & German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.

Johannes Kornhuber (J)

Department of Psychiatry and Psychotherapy, Friedrich-Alexander-University Erlangen, Erlangen, Germany.

Bernhard Landwehrmeyer (B)

Department of Neurology, University of Ulm, Ulm, Germany.

Martin Lauer (M)

Department of Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany.

Jolina Lombardi (J)

Department of Neurology, University of Ulm, Ulm, Germany.

Albert Ludolph (A)

Department of Neurology, University of Ulm, Ulm, Germany; German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany.

Felix Müller-Sarnowski (F)

Center for Cognitive Disorders, Department of Psychiatry and Psychotherapy, Technische Universität München, München, Germany.

Maryna Polyakova (M)

Max Planck Institute for Human Cognitive and Brain Sciences Leipzig & Clinic for Cognitive Neurology, University Hospital Leipzig, Germany.

Catharina Prix (C)

Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität (LMU) München, München, Germany.

Johannes Prudlo (J)

Department of Neurology, Rostock University Medical Center & German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.

Frank Regenbrecht (F)

Max Planck Institute for Human Cognitive and Brain Sciences Leipzig & Clinic for Cognitive Neurology, University Hospital Leipzig, Germany.

Carola Roßmeier (C)

Center for Cognitive Disorders, Department of Psychiatry and Psychotherapy, Technische Universität München, München, Germany.

Anja Schneider (A)

Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Medicine Bonn & DZNE Bonn, Bonn, Germany.

Jens Wiltfang (J)

Department of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany; German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany; Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal.

Markus Otto (M)

Department of Neurology, University of Ulm, Ulm, Germany.

Janine Diehl-Schmid (J)

Center for Cognitive Disorders, Department of Psychiatry and Psychotherapy, Technische Universität München, München, Germany; Munich Cluster for Systems Neurology (SyNergy), München, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH